NCT04039607 2026-04-06CheckMate 9DWBristol-Myers SquibbPhase 3 Active not recruiting732 enrolled 3 FDA
NCT04720716 2026-03-19A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCInnovent Biologics (Suzhou) Co. Ltd.Phase 3 Completed344 enrolled
NCT01658878 2025-12-24CheckMate040Bristol-Myers SquibbPhase 1/2 Completed657 enrolled 57 charts 5 FDA
NCT03412773 2025-10-14A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)BeiGenePhase 3 Completed684 enrolled 43 charts